{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:26:37Z","timestamp":1773966397205,"version":"3.50.1"},"reference-count":132,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":107,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["KU-2688\/2-1"],"award-info":[{"award-number":["KU-2688\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["KU-2688\/2-2"],"award-info":[{"award-number":["KU-2688\/2-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["SFB1292\/2\/TP12"],"award-info":[{"award-number":["SFB1292\/2\/TP12"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1053\/j.seminhematol.2025.09.001","type":"journal-article","created":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T03:49:33Z","timestamp":1757821773000},"page":"196-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tailoring intensive and less-intensive treatment in acute myeloid leukemia"],"prefix":"10.1053","volume":"62","author":[{"given":"Carolin","family":"Seeling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.M.","family":"K\u00fchn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1053\/j.seminhematol.2025.09.001_bib0001","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.09.001_bib0002","first-page":"485","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates","year":"1973","journal-title":"Cancer Chemother Rep"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.09.001_bib0003","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.09.001_bib0004","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nrc.2016.3","article-title":"Leukaemia \u201cfirsts\u201d in cancer research and treatment","volume":"16","author":"Greaves","year":"2016","journal-title":"Nat Reviews Can"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.09.001_bib0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.17652","article-title":"Comparison of antifungal prophylaxis drugs in patients with hematological disease or undergoing hematopoietic stem cell transplantation","volume":"3","author":"Wang","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"21","key":"10.1053\/j.seminhematol.2025.09.001_bib0006","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.09.001_bib0007","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/s41375-023-01999-6","article-title":"Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients","volume":"37","author":"Jahn","year":"2023","journal-title":"Leukemia"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.09.001_bib0008","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-020-1089-8","article-title":"Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial","volume":"26","author":"Burd","year":"2020","journal-title":"Nat Med"},{"issue":"7728","key":"10.1053\/j.seminhematol.2025.09.001_bib0009","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"issue":"23","key":"10.1053\/j.seminhematol.2025.09.001_bib0010","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1053\/j.seminhematol.2025.09.001_bib0011","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Network","year":"2013","journal-title":"N Engl J Med"},{"issue":"7218","key":"10.1053\/j.seminhematol.2025.09.001_bib0012","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/nature07485","article-title":"DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome","volume":"456","author":"Ley","year":"2008","journal-title":"Nature"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.09.001_bib0013","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.09.001_bib0014","unstructured":"Surveillance, epidemiology, and end results (SEER) US county populations 1969-2023. www.seer.cancer.gov\/popdata (accessed August 19, 2025)."},{"issue":"17","key":"10.1053\/j.seminhematol.2025.09.001_bib0015","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1182\/blood-2011-12-379008","article-title":"Acute myeloid leukemia in the real world: why population-based registries are needed","volume":"119","author":"Juliusson","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.09.001_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2025.102527","article-title":"Fitness in acute myeloid leukemia, state of the art and future directions","volume":"83","author":"Palmieri","year":"2025","journal-title":"Curr Opin Pharmacol"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.09.001_bib0017","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2024013744","article-title":"Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"9","author":"Venditti","year":"2025","journal-title":"Blood Adv"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.09.001_bib0018","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2012.303","article-title":"Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making","volume":"27","author":"Ferrara","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.09.001_bib0019","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3324\/haematol.2019.245803","article-title":"Geriatric assessment in older patients with a hematologic malignancy: a systematic review","volume":"105","author":"Scheepers","year":"2020","journal-title":"Haematologica"},{"issue":"26","key":"10.1053\/j.seminhematol.2025.09.001_bib0020","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"25","key":"10.1053\/j.seminhematol.2025.09.001_bib0021","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","article-title":"A randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients","volume":"125","author":"Burnett","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.09.001_bib0022","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/JCO.24.00235","article-title":"Single or double induction with 7\u202f+\u202f3 containing standard or high-dose daunorubicin for newly diagnosed AML: the randomized DaunoDouble trial by the study alliance leukemia","volume":"43","author":"R\u00f6llig","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.09.001_bib0023","series-title":"ASH Annual Meeting Abstract: Blood","first-page":"218","article-title":"10 Year follow-up of CALGB 10603\/ratify: midostaurin versus Placebo plus intensive chemotherapy in newly diagnosed FLT3 mutant acute myeloid leukemia patients aged 18-60 years","volume":"144","author":"Stone","year":"2024"},{"issue":"10388","key":"10.1053\/j.seminhematol.2025.09.001_bib0024","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2025.09.001_bib0025","series-title":"ASH Annual Meeting Abstract: Blood","first-page":"972","article-title":"Quantum-first: safety by treatment phase and by age in newly diagnosed (nd) patients (pts) with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) positive acute myeloid leukemia (AML)","volume":"142","author":"Erba","year":"2023"},{"issue":"9825","key":"10.1053\/j.seminhematol.2025.09.001_bib0026","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.09.001_bib0027","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novoacute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2018","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.09.001_bib0028","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of Gemtuzumab Ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1053\/j.seminhematol.2025.09.001_bib0029","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"issue":"32","key":"10.1053\/j.seminhematol.2025.09.001_bib0030","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of Gemtuzumab Ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1053\/j.seminhematol.2025.09.001_bib0031","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1182\/blood.V118.21.79.79","article-title":"Addition of Gemtuzumab Ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study","volume":"118","author":"Delaunay","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.09.001_bib0032","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.09.001_bib0033","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1200\/JCO.19.01406","article-title":"Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 phase III study","volume":"38","author":"Schlenk","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.09.001_bib0034","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3026(23)00089-3","article-title":"Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09\u201309): a randomised, open-label, multicentre, phase 3 trial","volume":"10","author":"D\u00f6hner","year":"2023","journal-title":"Lancet Haematol"},{"issue":"26","key":"10.1053\/j.seminhematol.2025.09.001_bib0035","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional Cytarabine plus Daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.09.001_bib0036","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol"},{"issue":"16","key":"10.1053\/j.seminhematol.2025.09.001_bib0037","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/bloodadvances.2023010276","article-title":"A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial","volume":"7","author":"Othman","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.09.001_bib0038","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.09.001_bib0039","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70198","article-title":"A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 mutated AML in MRD-negative remission after intensive induction","volume":"9","author":"D\u00f6hner","year":"2025","journal-title":"Hemasphere"},{"issue":"22","key":"10.1053\/j.seminhematol.2025.09.001_bib0040","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1182\/blood.2022016567","article-title":"Pre-transplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines post-transplant clinical outcome","volume":"140","author":"Loo","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.09.001_bib0041","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.22.00715","article-title":"Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia","volume":"41","author":"Grob","year":"2023","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1053\/j.seminhematol.2025.09.001_bib0042","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.1182\/bloodadvances.2024013758","article-title":"Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin","volume":"8","author":"R\u00fccker","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.09.001_bib0043","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1038\/bcj.2017.45","article-title":"Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia","volume":"7","author":"Jaramillo","year":"2017","journal-title":"Blood Cancer J"},{"issue":"16","key":"10.1053\/j.seminhematol.2025.09.001_bib0044","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1182\/bloodadvances.2020002511","article-title":"Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome","volume":"4","author":"Dumas","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.09.001_bib0045","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","article-title":"Cytarabine dose for acute myeloid leukemia","volume":"364","author":"L\u00f6wenberg","year":"2011","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1053\/j.seminhematol.2025.09.001_bib0046","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the Medical Research Council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.09.001_bib0047","article-title":"Intermediate-dose cytarabine as postinduction AML therapy","volume":"4","author":"Hunault","year":"2025","journal-title":"NEJM \u00c9vid"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.09.001_bib0048","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1053\/j.seminhematol.2025.09.001_bib0049","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3 \u2013Internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.09.001_bib0050","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","article-title":"Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial","volume":"10","author":"Xuan","year":"2023","journal-title":"Lancet Haematol"},{"issue":"25","key":"10.1053\/j.seminhematol.2025.09.001_bib0051","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.2012.46.4990","article-title":"Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial","volume":"31","author":"Serve","year":"2013","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1053\/j.seminhematol.2025.09.001_bib0052","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(15)00362-9","article-title":"Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial","volume":"16","author":"R\u00f6llig","year":"2015","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1053\/j.seminhematol.2025.09.001_bib0053","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1053\/j.seminhematol.2025.09.001_bib0054","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.09.001_bib0055","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/s41375-025-02531-8","article-title":"Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2025","journal-title":"Leukemia"},{"issue":"22","key":"10.1053\/j.seminhematol.2025.09.001_bib0056","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood.2024027217","article-title":"Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML","volume":"145","author":"Lu","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.09.001_bib0057","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","article-title":"Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia In vivo","volume":"27","author":"Borkin","year":"2015","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.09.001_bib0058","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","article-title":"Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia","volume":"6","author":"K\u00fchn","year":"2016","journal-title":"Can Discovery"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.09.001_bib0059","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL- rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1053\/j.seminhematol.2025.09.001_bib0060","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood.2020005037","article-title":"Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition","volume":"136","author":"Dzama","year":"2020","journal-title":"Blood"},{"issue":"6477","key":"10.1053\/j.seminhematol.2025.09.001_bib0061","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1126\/science.aax5863","article-title":"Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia","volume":"367","author":"Uckelmann","year":"2020","journal-title":"Science"},{"issue":"7954","key":"10.1053\/j.seminhematol.2025.09.001_bib0062","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.09.001_bib0063","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with Revumenib for KMT2A -rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.09.001_bib0064","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood.2025028357","article-title":"Menin inhibition with revumenib for NPM1-mutated (NPM1m) relapsed or refractory acute myeloid leukemia: AUGMENT-101","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.09.001_bib0065","series-title":"Blood, ASH Annual Meeting","article-title":"Phase 1b study of Menin-KMT2A inhibitor Bleximenib in combination with intensive chemotherapy in newly diagnosed acute myeloid leukemia with or alterations","volume":"#215","author":"Reicher","year":"2024"},{"key":"10.1053\/j.seminhematol.2025.09.001_bib0066","series-title":"Blood, ASH Annual Meeting","article-title":"Ziftomenib combined with intensive induction (7+3) in newly diagnosed m or -r acute myeloid leukemia: interim phase 1a results from KOMET-007","volume":"#214","author":"Zeidan","year":"2024"},{"issue":"21","key":"10.1053\/j.seminhematol.2025.09.001_bib0067","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2025.09.001_bib0068","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"16","key":"10.1053\/j.seminhematol.2025.09.001_bib0069","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and Azacitidine in IDH1 -mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.09.001_bib0070","doi-asserted-by":"crossref","unstructured":"Montesinos P., Marchione D.M., Recher C., et al. Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML. Blood Adv. 2025 Jul 24:bloodadvances.2025016399. Online ahead of print.","DOI":"10.1182\/bloodadvances.2025016399"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.09.001_bib0071","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/s41375-023-01999-6","article-title":"Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients","volume":"37","author":"Jahn","year":"2023","journal-title":"Leukemia"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.09.001_bib0072","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/ajh.27070","article-title":"Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants","volume":"98","author":"Bataller","year":"2023","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.09.001_bib0073","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminhematol.2025.09.001_bib0074","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1182\/bloodadvances.2024013685","article-title":"Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy","volume":"8","author":"Hoff","year":"2024","journal-title":"Blood Adv"},{"issue":"26","key":"10.1053\/j.seminhematol.2025.09.001_bib0075","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1182\/blood.2024026925","article-title":"Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML","volume":"144","author":"Lachowiez","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.09.001_bib0076","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","article-title":"Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax","volume":"8","author":"Bataller","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.09.001_bib0077","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.27138","article-title":"Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: genotype signatures for response and survival among 301 consecutive patients","volume":"99","author":"Gangat","year":"2023","journal-title":"Am J Hematol"},{"issue":"21","key":"10.1053\/j.seminhematol.2025.09.001_bib0078","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.09.001_bib0079","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.09.001_bib0080","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood.2022015832","article-title":"Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy","volume":"140","author":"Zeidan","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.09.001_bib0081","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3390\/cancers14092342","article-title":"Azacitidine vs Decitabine in unfit newly diagnosed acute myeloid leukemia patients: results from the PETHEMA registry","volume":"14","author":"Labrador","year":"2022","journal-title":"Cancers"},{"key":"10.1053\/j.seminhematol.2025.09.001_bib0082","article-title":"Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy","volume":"126","author":"Maurillo","year":"2023","journal-title":"Leuk Res"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.09.001_bib0083","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1358\/dof.2013.38.8.1980499","article-title":"SGI-110: DNA methyltransferase inhibitor oncolytic","volume":"38","author":"Griffiths","year":"2013","journal-title":"Drugs Futur"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.09.001_bib0084","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(17)30576-4","article-title":"Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1\/2 trial","volume":"18","author":"Kantarjian","year":"2017","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1053\/j.seminhematol.2025.09.001_bib0085","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1182\/bloodadvances.2023010179","article-title":"Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study","volume":"7","author":"Fenaux","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.09.001_bib0086","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/bjh.19741","article-title":"Oral decitabine\/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: a randomised, crossover, registration, pharmacokinetics study","volume":"205","author":"Geissler","year":"2024","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.09.001_bib0087","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.09.001_bib0088","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.09.001_bib0089","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00277-024-05891-w","article-title":"A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?","volume":"104","author":"Solana-Altabella","year":"2024","journal-title":"Ann Hematol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.09.001_bib0090","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2023-187383","article-title":"A randomized phase 2 trial of 28-day (Arm A) versus 14-day (Arm B) schedule of venetoclax\u202f+\u202fazacitidine in newly diagnosed acute myeloid leukemia patients \u2265 60 years","volume":"142","author":"Borate","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.09.001_bib0091","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-025-01269-x","article-title":"Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients","volume":"15","author":"Willekens","year":"2025","journal-title":"Blood Cancer J"},{"issue":"24","key":"10.1053\/j.seminhematol.2025.09.001_bib0092","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1158\/1078-0432.CCR-21-4037","article-title":"Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy","volume":"28","author":"Deng","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2025.09.001_bib0093","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1200\/JCO.2024.42.16_suppl.6541","article-title":"Safety and efficacy of lisaftoclax, a novel BCL-2 inhibitor, in combination with azacitidine in patients with treatment-na\u00efve or relapsed or refractory acute myeloid leukemia","volume":"42","author":"Wei","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.09.001_bib0094","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2023-188489","article-title":"Safety and efficacy of Lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in relapsed or refractory (R\/R) or treatment-na\u00efve (TN) patients (Pts) with acute myeloid leukemia (AML), Myelodysplastic Syndrome (MDS), or other myeloid neoplasms","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"issue":"24","key":"10.1053\/j.seminhematol.2025.09.001_bib0095","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"25","key":"10.1053\/j.seminhematol.2025.09.001_bib0096","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.2022016963","article-title":"Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.09.001_bib0097","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JCO.20.01632","article-title":"Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with Azacitidine for newly diagnosed acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.09.001_bib0098","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/10428194.2022.2136952","article-title":"Venetoclax-based salvage therapy in patients with relapsed\/refractory acute myeloid leukemia previously treated with FLT3 or IDH1\/2 inhibitors","volume":"64","author":"Bewersdorf","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2025.09.001_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106942","article-title":"Efficacy of FLT3 and IDH1\/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax","volume":"122","author":"Bewersdorf","year":"2022","journal-title":"Leuk Res"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.09.001_bib0100","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2023-173033","article-title":"A comparison of acute myeloid leukemia (AML) regimens: hypomethylating agents combined with Ivosidenib or Venetoclax in newly diagnosed patients with IDH1 mutations: a real-world evidence study","volume":"142","author":"Smith","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.09.001_bib0101","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminhematol.2025.09.001_bib0102","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","article-title":"Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML","volume":"7","author":"Botton","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.09.001_bib0103","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","article-title":"A phase ib\/II study of Ivosidenib with venetoclax \u00b1 azacitidine in IDH1-mutated myeloid malignancies","volume":"4","author":"Lachowiez","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.09.001_bib0104","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2024-200393","article-title":"A phase ib\/II study of Ivosidenib with venetoclax \u00b1 azacitidine in IDH1-mutated hematologic malignancies: a 2024 update","volume":"144","author":"Marvin-Peek","year":"2024","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminhematol.2025.09.001_bib0105","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, Venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.09.001_bib0106","doi-asserted-by":"crossref","first-page":"220-","DOI":"10.1182\/blood-2024-210891","article-title":"Long-term survival outcomes and cytogenetic\/molecular patterns of relapse in adults with FLT3-mutated AML receiving frontline triplet therapy with a hypomethylating agent, Venetoclax and FLT3 inhibitor","volume":"144","author":"Short","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.09.001_bib0107","series-title":"HemaSphere, EHA Annual Meeting","first-page":"4617","article-title":"VICEROY: a phase I\/II study of Gilteritinib, Venetoclax and Azacitidine combination in patients with newly diagnosed FLT3-mutated acute myeloid leukemia","volume":"8","author":"Daver","year":"2024"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.09.001_bib0108","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","article-title":"Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study","volume":"25","author":"Daver","year":"2024","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.09.001_bib0109","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood-2023-173413","article-title":"Pivekimab Sunirine (PVEK, IMGN632), a CD123-targeting antibody-drug conjugate, in combination with Azacitidine and Venetoclax in patients with newly diagnosed acute myeloid leukemia","volume":"142","author":"Daver","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.09.001_bib0110","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.3324\/haematol.2022.282160","article-title":"Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax","volume":"108","author":"Rausch","year":"2022","journal-title":"Haematologica"},{"issue":"23","key":"10.1053\/j.seminhematol.2025.09.001_bib0111","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO-25-00914","article-title":"Azacitidine, Venetoclax, and Revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML","volume":"43","author":"Zeidner","year":"2025","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.09.001_bib0112","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1182\/blood-2024-199170","article-title":"Ziftomenib combined with Venetoclax\/Azacitidine in relapsed\/refractory NPM1-m or KMT2A-r acute myeloid leukemia: interim phase 1a results from KOMET-007","volume":"144","author":"Fathi","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.09.001_bib0113","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(24)00033-4","article-title":"Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study","volume":"11","author":"Bazinet","year":"2024","journal-title":"Lancet Haematol"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2025.09.001_bib0114","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1200\/JCO.2025.43.16_suppl.6504","article-title":"An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: results from a phase 2 cohort of 101 pts","volume":"43","author":"Zeidan","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.09.001_bib0115","series-title":"HemaSphere, EHA Annual Meeting","first-page":"85","article-title":"All-oral decitabine-cedazuridine (DEC-C)\u202f+\u202fvenetoclax (VEN) in patients with newly diagnosed acute myeloid leukemia (AML) ineligible for induction chemotherapy: phase 1\/2 clinical trial results","volume":"9","author":"Roboz","year":"2025"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.09.001_bib0116","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1182\/blood-2023-182944","article-title":"Phase ib\/2 study of oral decitabine\/Cedazuridine (ASTX727) and Venetoclax in combination with the targeted mutant IDH1 inhibitor Ivosidenib or the targeted mutant IDH2 inhibitor Enasidenib: 2023 update","volume":"142","author":"Atluri","year":"2023","journal-title":"Blood"},{"issue":"24","key":"10.1053\/j.seminhematol.2025.09.001_bib0117","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO-25-00640","article-title":"Outcomes of frontline triplet regimens with a hypomethylating agent, venetoclax, and isocitrate dehydrogenase inhibitor for intensive chemotherapy-Ineligible patients with isocitrate dehydrogenase\u2013Mutated AML","volume":"43","author":"DiNardo","year":"2025","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.09.001_bib0118","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/blood-2024-204375","article-title":"Phase I\/II study of the all-oral combination of Revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in R\/R AML","volume":"144","author":"Issa","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.09.001_bib0119","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1182\/blood-2024-198928","article-title":"Personalized oral maintenance therapy with decitabine\/cedazuridine (ASTX727) combined with a molecularly targeted agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in acute myeloid leukemia in first remission","volume":"144","author":"Bazinet","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.09.001_bib0120","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/bloodadvances.2024014014","article-title":"Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study","volume":"9","author":"Wolach","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.09.001_bib0121","doi-asserted-by":"crossref","first-page":"E80","DOI":"10.1002\/ajh.26846","article-title":"Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax","volume":"98","author":"Candoni","year":"2023","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.09.001_bib0122","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood-2023-178505","article-title":"Real world outcome of unfit patients with acute myeloid leukemia treated with the combination venetoclax plus hypomethylating agents in the Gimema AML2320 observational trial","volume":"142","author":"Venditti","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.09.001_bib0123","first-page":"6443","article-title":"P544: molecular predictors of response and survival in treatment-na\u00efve patients with acute myeloid leukemia following venetoclax and hypomethylating agents","author":"Johnson","year":"2022","journal-title":"HemaSphere"},{"issue":"13","key":"10.1053\/j.seminhematol.2025.09.001_bib0124","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","article-title":"Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia","volume":"6","author":"Matthews","year":"2022","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.09.001_bib0125","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood-2023-187331","article-title":"Real world use of azacitidine and venetoclax in acute myeloid leukemia in frontline and relapse\/refractory settings: a multicentric study from French Auraml Group","volume":"142","author":"Gross","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.09.001_bib0126","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1016\/j.clml.2023.02.002","article-title":"Early real-world first-line treatment with venetoclax plus HMAs versus HMA monotherapy among patients with AML in a predominately US community setting","volume":"23","author":"Gershon","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.09.001_bib0127","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/ejh.14278","article-title":"Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy","volume":"113","author":"Acker","year":"2024","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.09.001_bib0128","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00277-021-04465-4","article-title":"Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial","volume":"100","author":"Heuser","year":"2021","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.09.001_bib0129","first-page":"E63","article-title":"Venetoclax duration (14 vs. 21 vs. 28\u2009days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: comparative analysis of response, toxicity, and survival","volume":"99","author":"Karrar","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.09.001_bib0130","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-025-01324-7","article-title":"Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine-venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net","volume":"15","author":"Kanaya","year":"2025","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.09.001_bib0131","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1182\/blood-2024-209246","article-title":"Optimizing venetoclax duration in combination with hypomethylating agents for newly diagnosed AML: impact on treatment response and survival outcomes","volume":"144","author":"Ginosyan","year":"2024","journal-title":"Blood"},{"issue":"S1","key":"10.1053\/j.seminhematol.2025.09.001_bib0132","first-page":"72","article-title":"A phase 1B study of the menin-KMT2A inhibitor JNJ-75276617 in combination with venetoclax and azacitidine in relapsed\/refractory acute myeloid leukemia with alterations in KMT2A or NPM1. HemaSphere","volume":"8","author":"Wei","year":"2024","journal-title":"EHA Annual Meeting"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T22:22:11Z","timestamp":1773958931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196325000381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":132,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0037196325000381"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.09.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tailoring intensive and less-intensive treatment in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}